Novo Nordisk Extends Slide After Announcing Price-Cuts For Blockbuster Obesity Drugs
--------------------------------------------------------------------
Source: Zero Hedge
Published: 2026-02-25 01:30 UTC+10:00
Section: General
Factuality Score: 100
Opinion Category: Neutral
Topics: Business, Science, Economy & Finance, Financial Markets, Drugs, Space
--------------------------------------------------------------------
Snippet:
Novo Nordisk shares in Copenhagen can't catch a bid. The liquidation is accelerating again after a Bloomberg headline on Tuesday morning: the Danish drugmaker will slash U.S. list prices for Wegovy and Ozempic next year. The move suggests that the new CEO is pursuing market share amid intensifying competition in the GLP-1 space.
--------------------------------------------------------------------